Malignant solid neoplasm, BRAF-mutated
Revision as of 23:00, 8 January 2020 by Esigworth (talk | contribs) (→Dabrafenib & Trametinib {{#subobject:b078c2|Regimen=1}})
2 regimens on this page
2 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Dabrafenib & Trametinib
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Subbiah et al. 2017 (BRF117019) | Phase II |
Note: only partial results have been published to date.
Biomarker eligibility criteria
- Gene: BRAF V600E
- Alteration: substitution
- Acceptable methods of measurement: archival or fresh tumor tissue
Preceding treatment
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
References
- BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed
Vemurafenib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hyman et al. 2015 (VE-BASKET) | Phase II |
| Hainsworth et al. 2018 (MyPathway) | Phase IIa |
Eligibility criteria
- VE-BASKET: BRAF p.V600 mutations
- MyPathway: BRAF p.V600E mutation without coexisting KRAS mutations, or other BRAF mutations
Chemotherapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
Continued indefinitely
References
- VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-736. link to original article contains protocol link to PMC article PubMed
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed